Evigrade
DrugsCosmetic ingredientsCalculatorsInteractionsEvigrade SkinEvigrade Meds ↗
ConditionsJournalMethodologyPro for practitioners
ESRU

Levodopa + Carbidopa + Entacapone

Triple fixed-dose combination: dopamine precursor, peripheral decarboxylase inhibitor, and COMT inhibitor

ATC code: N04BA03(Levodopa, decarboxylase inhibitor and COMT inhibitor)

Updated · Methodology

Indications

B

Parkinson's disease

Second line

Parkinson's disease in patients with wearing-off on levodopa-carbidopa therapy. Per MDS 2018 and SEN 2024, the triple combination is second-line for motor fluctuations. Dose: individualized, based on prior levodopa dose; standard tablets 50/12.5/200, 75/18.75/200, 100/25/200, 125/31.25/200, 150/37.5/200, 200/50/200 mg 4–10 times daily depending on regimen. Not first-line in levodopa-naïve patients.

Sources

  1. AEMPS: Ficha técnica de Levodopa + Carbidopa + Entacapona (2024)
  2. Movement Disorders: International Parkinson and movement disorder society evidence‐based medicine review: Update on treatments for the motor symptoms of Parkinson's disease (2018)
  3. Cochrane Database Syst Rev: Catechol-O-methyltransferase inhibitors for levodopa-induced complications in Parkinson's disease. (2004)
  4. Ther Clin Risk Manag: Levodopa/carbidopa/entacapone versus levodopa/dopa-decarboxyiase inhibitor for the treatment of Parkinson's disease: systematic review, meta-analysis, and economic evaluation. (2018)

ICD-10: G20 · ICD-11: 8A00.0

How to read tiers A–F
  • AStrong evidence – first or second line in international guidelines
  • BRecommended in selected cases
  • CStudy data contradict each other
  • DBenefit not proven, no documented harm
  • FDocumented harm, or risk without benefit

Mechanism of action

Levodopa crosses the blood-brain barrier and is converted to dopamine in the substantia nigra and striatum, replenishing the dopamine deficit in Parkinson's. Carbidopa inhibits peripheral decarboxylase – more levodopa reaches the brain and dose-related nausea decreases. Entacapone reversibly inhibits peripheral catechol-O-methyltransferase (COMT) – prolongs levodopa T½ and reduces wearing-off. The triple combination smooths dopamine fluctuations in advanced disease.

Safety

Contraindications

  • Hypersensitivity
  • Angle-closure glaucoma
  • Pheochromocytoma
  • Severe hepatic impairment
  • History of neuroleptic malignant syndrome or nontraumatic rhabdomyolysis
  • Melanoma or suspicious skin lesions (levodopa may exacerbate)
  • Concomitant nonselective MAOI or use within 14 days of stopping

Serious adverse effects

  • Impulse-control disorders (pathological gambling, hypersexuality, compulsive shopping)
  • Cardiac arrhythmias
  • Dopamine dysregulation syndrome
  • Entacapone hepatotoxicity (rare, monitor ALT on suspicion)

Common adverse effects

  • Dyskinesias (with long-term use)
  • Nausea, vomiting
  • Orthostatic hypotension
  • Daytime sleepiness and sleep attacks
  • Orange urine and sweat
  • Dry mouth
  • Insomnia
  • Hallucinations (in older adults, dementia)

Pregnancy: can you take Levodopa + Carbidopa + Entacapone?

Use when clearly needed. Parkinson's in young women is rare; decisions on continuation are made with neurology and obstetrics.

Breastfeeding: can you take Levodopa + Carbidopa + Entacapone?

Suppresses lactation by lowering prolactin. Hale L4. If therapy continues, switch to formula feeding.

Calculate RID

Reference information, not a clinical decision. Discuss feeding pauses or changes with your physician or an IBCLC.

Practical notes

Drug interactions

With MAOIs (except selegiline and rasagiline at standard doses) – hypertensive crisis; observe 14-day washout. With iron – levodopa absorption decreases; separate by ≥2 hours. With dietary protein – competition for blood-brain barrier transport; take 30 minutes before or 60 minutes after meals.

Monitoring

BP at start and titration (orthostatic hypotension risk). Entacapone gives urine an orange tint – normal finding, reassure the patient.

Check interaction with another drug

Opens the checker prefilled with this drug. Pick the second one from your regimen.

Open checker

Summary of a multi-drug list →

Medicine list: everything you take in one place →

Frequently asked

What is Levodopa + Carbidopa + Entacapone used for?

Levodopa + Carbidopa + Entacapone is evaluated for the following indications with varying evidence strength: Parkinson's disease (evidence tier B). See the full indication matrix with dosing and citations above on this page.

What are the side effects of Levodopa + Carbidopa + Entacapone?

Common side effects of Levodopa + Carbidopa + Entacapone (≥ 1 in 100): Dyskinesias (with long-term use), Nausea, vomiting, Orthostatic hypotension, Daytime sleepiness and sleep attacks, Orange urine and sweat, Dry mouth. See the Safety section for uncommon and serious reactions.

Is Levodopa + Carbidopa + Entacapone safe during pregnancy?

Use when clearly needed. Parkinson's in young women is rare; decisions on continuation are made with neurology and obstetrics.

Is Levodopa + Carbidopa + Entacapone compatible with breastfeeding?

Suppresses lactation by lowering prolactin. Hale L4. If therapy continues, switch to formula feeding.

Who should not take Levodopa + Carbidopa + Entacapone?

Levodopa + Carbidopa + Entacapone is contraindicated in: Hypersensitivity; Angle-closure glaucoma; Pheochromocytoma; Severe hepatic impairment; History of neuroleptic malignant syndrome or nontraumatic rhabdomyolysis. Full list in the Safety section.

Other drugs in this group

Bromocriptine, Cabergoline, Pramipexole, Rasagiline, Ropinirole, Selegiline